Myriad Can't Patent Cancer Genes, ACLU Tells High Court

Law360, New York (January 28, 2013, 4:36 PM EST) -- Patents on breast cancer genes isolated by Myriad Genetics Inc. should be invalidated because they are no different from DNA found in nature and are not based on any inventive concept, the American Civil Liberties Union told the U.S. Supreme Court on Wednesday.

In its opening brief in the case, which the high court agreed to hear in November, the ACLU argued that Myriad's gene patents have had a chilling effect on breast cancer research, and that even if they were valid, the patents violate the...
To view the full article, register now.